Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Published date:
02/24/2021
Excerpt:
...gilteritinib also displayed potency against ROS1 fusion gene-expressing lung cancer cell lines (HCC78 cells harbor SLC34A2-ROS1 and JFCR-168 harbor CD74-ROS1…)